Semaglutide demonstrates superior weight loss and glycemic control compared to other GLP-1 receptor agonists like liraglutide and exenatide, with clinical trials showing enhanced patient adherence through once-weekly dosing
Patients on such combinations require regular monitoring of INR (International Normalized Ratio) to ensure safe clotting parameters
Outcomes and definitions Primary outcomes included: Clinical Pregnancy: Identified by positive serum -hCG ( 25 mIU/mL), pregnancy-related diagnoses, positive pregnancy test, or related procedural and delivery codes
The most obvious substitute for Ozempic in the UK is Wegovy, as its made by the same manufacturer using the same active ingredient (semaglutide), but its designed specifically for weight loss
In a real-world observational study of GLP-1 receptor agonist users, nutritional deficiencies were diagnosed in 12.7% by 6 months and 22.4% by 12 months , with vitamin D deficiency most common